P42med

P42med is an innovative early-stage biotechnology startup focused on developing cutting-edge in silico drug design solutions to address the challenges of GPCR modulation. Leveraging the power of computational approaches, P42med aims to design allosteric transmembrane modulators, which hold the potential to fine-tune receptor activity, increasing specificity and signaling bias. This unique focus on allosteric modulation may open new avenues for drug discovery and development, targeting a wide range of therapeutics areas, including neurology, oncology, and metabolic disorders. Founded by a group of dedicated co-founders with expertise in computational biology, biophysics, and bioinformatics, P42med has successfully bootstrapped its operations since its inception. The team has developed a robust in silico pipeline and demonstrated promising activity for both allosteric and orthosteric modulators of GPCRs, positioning P42med at the forefront of innovative drug design strategies. By bridging the gap between fundamental biomedical research and the pharmaceutical industry, P42med aims to accelerate the translation of groundbreaking research into life-changing medicines.